Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will play, I will put in a huge buy order.
You know the drill.
EMBI Price is 9.802 USD today.
1 year Skye Bioscience Forecast: 9.654019 *
5 year Skye Bioscience Forecast: 10.724 *
Alert! Please note that this asset seems fundamentally flawed meaning that we can't recommend investing it. This could be for various reasons: abandoned by the developers, faulty code, intentionally malicious project, etc.
About the Emerald Bioscience, Inc. stock forecast
As of 2021 March 06, Saturday current price of EMBI stock is 9.802$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).
Emerald Bioscience, Inc. has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame.
Our site uses a custom algorithm based on Deep Learning that helps our users to decide if EMBI could be a good portfolio addition. These predictions take several variables into account such as volume changes, price changes, market cycles, similar stocks.
Future price of the stock is predicted at 9.654019$ (30.78% ) after a year according to our prediction system.
This means that if you invested $100 now, your current investment may be worth 130.78$ on 2022 March 06, Sunday.
This means that this stock is suited as a new addition to your portfolio as trading bullish markets is always a lot easier.
Skye Bioscience stock forecast, EMBI price prediction: Buy or sell Emerald Bioscience, Inc. shares?
by Gov Capital
EMBI Price is 9.802 USD today.
1 year Skye Bioscience Forecast: 9.654019 *
5 year Skye Bioscience Forecast: 10.724 *
No fable true story. Holding onto my shares like it’s platinum.
From The Article; David Stone said it best;
How to beat Wall Street:
You buy. And you hold. You hold forever. You never, ever sell until your thesis plays out. If the stock drops, you should be thrilled. You can buy more at a cheaper price. You should laugh like an invincible warrior facing down an army.
“You want this stock? You want MY STOCK? Then you’re gonna have to kill me and dig up the cemetery because I am taking this stock to the grave.”
If you hold on to your shares, Wall Street can never own them.
This will frustrate them. If enough investors buy and hold a stock because it’s a great company with great growth prospects, then the vampire squid will move on.
Wall Street’s biggest weapon is fear. Fear in the face of an uncertain future.
If you sell, they win.
If you hold, you win.
Don’t let Wall Street steal your gems.”
All, buy some. Give it u push for a fresh start monday !!!
Yea, this is my only OTC that has held up. Everything else has been bloody . I think we are ready for our next leg up here.
Funny, nobody is selling. All red, we are holding up. This is going to be something next week, when stocks will rise.
Good time to buy here. I plan on being here for a while. I expect some strong momentum soon.
GL
Finaly order went, thank you for the shares.
Could be fake walls today,
That’s how we win. Slow and steady wins the race. Product innovation and pioneering cannabinoid use will get us there.
I closed five positions with a high, could be, factor. The passed three weeks, were not realy funny on OTC, so I am going for a slower but sure pace. In EMBI/SKYE for one year now. And ready for the jump. GLTA
Let’s gain on positive proceeds!
I am done, loaded up. Now we can go up !
SKYE to 1 dollar by Q3-Q4, perhaps even earlier than that!
There is no call... it's just hold pattern or sideways with downward trend... load up under .08
Please do not add on my comment, make your own investements, no pump here. I think somebody made a mistake and put it online.
The reason I am buying/adding is... a think a saw a wrong share prediction update. Was 1$. Thats why I started 6 mnth ago. Or it was a typo, or this is going nuts. BTW, When is the call? Tomorrow?
reverse up
just added....
Meet you all on the MOON once SKYE reaches that $1 dollar.
I did mean University of Mississippi. Thank You!
If you mean University of Mississippi, no. Skye will be funding the trials (unless they get some sort of Gov't grant/funding).
Does anyone know if SKYE's clinical trials will be funded by MSU?
Thanks and good luck!
Good write up
Skye Bioscience Is Pursuing A New Kind Of Glaucoma Drug
https://finance.yahoo.com/news/skye-bioscience-pursuing-kind-glaucoma-140237389.html
Holding support well between 0.1150 and 0.13... Floor going in good opportunity to add.. looking good..
LOAD UP CANNABIS IS ON FIRE!!!!!!!
RM swell in progress...SKYE to a $1.00..bombshell_glaucoma_player.
Thanks for the shares.. Flippers gonna get smoked... Little Profit takers..
imo...first mj glaucoma patent..this ss...$5.00target...risky_flip.
ALL ABOARD!!!! (SKYE) PRICE IS CHURNING.... LOADING ZONE / LOAD UP.. UP TREND.
May see a 0.13 close here today...BOLLY BANDs ARE SMOKING...
Anything under 0.10 was Gift here way under valued...
Upward trend continues. Closing in on .12 this morning
Medical Cannabis Stocks (SKYE)
Medical cannabis is a type of therapy prescribed by doctors for health conditions and symptoms. This means patients can only access cannabis treatments with a prescription from their doctors. To date, the drug has been used to treat Alzheimer's, different forms of cancer, various mental health conditions, multiple sclerosis, nausea, and pain.
The industry has been moving forward since California became the first state to legalize medical pot in 1996. Research conducted in 2018 stated that Sanofi Aventis (SNY) and Merck (MRK) are among the top cannabis-related patent holders.1? Companies involved in the use of marijuana for medical uses are GW Pharmaceuticals (GWPH), Tilray (TLRY), Corbus Pharmaceuticals (CRBP), Cara Therapeutics (CARA), and Zynerba Pharmaceuticals (ZYNE).
source: Investopedia
Cannabis CEO Says Marijuana legalization within 2 years... https://www.cnbc.com/2021/01/27/tilray-ceo-expects-us-federal-cannabis-legalization-within-two-years.html
Congress working on Marijuana legislation..Good things are coming in Cannabis.. https://www.marijuanamoment.net/chuck-schumer-says-marijuana-reform-bills-are-being-merged-as-congress-moves-to-legalize/
I am hanging in there for a $1, or even a fourth of that. I guess I need to go ahead and dump in another 10k at this point.
patented mj eye therapy...$1...incoming. $SKYE
no shares under .068....accumulated $SKYE
I can't tell from where I am sitting.
Skye Bioscience, Inc., formerly Emerald Bioscience, Inc., is a biopharmaceutical company, which is engaged in engineering cannabinoid derivatives to treat glaucoma and other diseases. The Company is focused on discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. Its programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. CBDVHS is a prodrug of cannabidiol (CBD) that has demonstrated biological activity in prodrug form (CBDVHS) and as native (natural) CBD. The Company has chemically-modified the CBD molecule to improve on its known positive effects.
Emerald Bioscience Creates Unique Path to Prevent Blindness Using Patented Synthetic Cannabinoids
10:17 pm ET December 4, 2020 (Benzinga) Print
The rapid innovation and growth in biotechnology is being used to define, validate, and enhance therapeutic outcomes from cannabinoids. The results could prove highly valuable to patients, as well as the pharmaceutical sector and its investors.
That is according to Punit Dhillon, the recently appointed CEO at Emerald Bioscience Inc (OTC: EMBI), a San Diego-based biotech focused on cannabinoid-derived therapies for a spectrum of diseases with unmet medical needs. Through his various leadership roles at biopharmaceutical companies like OncoSec Medical Inc (NASDAQ: ONCS) and Inovio Pharmaceuticals Inc (NASDAQ: INO), Dhillon learned first-hand what it takes for biotech businesses to catalyze growth and provide well-differentiated approaches for the treatment of diseases.
Dhillon spoke with Benzinga about Emerald's proprietary technology which substantially enhances the local delivery, bioavailability, dosing, and – most importantly – potentially advantageous therapeutic effects of cannabinoids for diseases like glaucoma.
A First In Medicine: THC and CBD – the two major cannabinoids which act on specific receptors found on the endocannabinoid system – have been shown to maintain homeostasis in the body. Emerald’s research and development has further pushed the boundaries, bringing new ways to effect change on the endocannabinoid’s signalling pathways that involve a whole range of different physiological and pathological conditions.
“The endocannabinoid system is becoming increasingly recognized as an important system in the body that can be pharmacologically targeted for therapeutic benefits related to a myriad of diseases involving inflammation, pain, neurodegeneration, and immune modulation, to name a few."
Since Dhillon’s arrival, the firm has clarified a development path for its lead molecule.
"We're focusing our initial efforts on ocular opportunities, where there's been very little innovation, broadly speaking," the CEO said in reference to Emerald's clinical study of cannabis-infused treatments for glaucoma, the increase in intraocular pressure (IOP) that damages the retinal ganglion cells connected to the optic nerve, and causes irreversible loss of vision.
Using THC as medicine alone does have drawbacks, however. Specifically, THC is not concentrated enough to lower IOP. Additionally, the appearance of being under the influence and persistently low blood pressure are two other key detractors.
Emerald’s active pharmaceutical ingredients (API) overcome these common issues by enabling local delivery of more hydrophilic, comparatively minuscule THC doses directly to the eye, as an eyedrop. The drug's solubility offers deeper penetration into the eye where the THC conversion then delivers the molecule to the specific organ that regulates IOP.
“In our planned clinical study in humans, we are in fact going to have the benefit of using an agent that has already shown utility in humans – but our version has the basis to be very safe and far more effective."
“By controlling IOP, we can slow and preserve vision loss,” the CEO added. “Our mechanism is very unique compared to what exists. We’ve been able to deliver this and have an improvement over standard drugs.”
One Big Thing: There is a large subset of patients in the world who develop vision loss even while having controlled or normal IOP levels.
“The exact reason why these patients still suffer damage to their optic nerve and vision loss is not completely understood, but neurodegeneration is evident. Existing drugs offer no benefit for these patients," said Dhillon.
This area, according to the CEO, is where Emerald may inflict game-changing results.
“There is significant peer-reviewed literature to support the ability of cannabinoids, specifically THC, to provide neuroprotection of these cells that make up the optic nerve. There is nothing currently in the market that provides this neuroprotective benefit, making our mechanism very unique compared to what exists."
Path To Viability: Presently, Emerald’s work alongside a university that has a long-standing relationship at the federal level has given it a leg up in securing compelling proprietary technology.
"The University of Mississippi was given the first and only federal license to grow and conduct research on cannabis by the DEA going back 50 years. Their research produced the THCVHS and CBDVHS molecules that Emerald subsequently licensed from them," Dhillon said in reference to Emerald's fast-paced research and development.
Emerald’s products won’t be found at the storefront cannabis shop. Instead, the firm applies the full knowledge and capability of decades of R&D, clinical, and business development experience in the life sciences industry to advance differentiated, patented molecules through regulated processes, to validate their medical capabilities fully.
“The wider the "moat" of strong intellectual property and the stronger the data generated in well-designed clinical studies, the greater the potential interest a company with new medicines can generate from professional biotech investors and prospective pharmaceutical partners.”
Growth Prospects: Going forward, Emerald will look to do more preclinical assessments comparing its lead THCVHS compound to existing commercialized glaucoma drugs over their ability to reduce IOP and provide neuroprotection of the optic nerve.
If the firm can demonstrate superior IOP lowering and neuroprotection, then it's painting a new precedent for the treatment of glaucoma and potentially other diseases.
"We aim to start our first human study in the third quarter of 2021,” Dhillon added.
“Because of the nature of this disease – our monitoring period for each patient will be measured in just weeks – the overall study will be fast and relatively low-cost, and the study is designed in a manner that will also provide an early indication of efficacy not normally available in typical phase 1 studies.”
On another note, Emerald is moving forward on a rebranding process to represent the change in leadership and reinvigorated focus to enter the clinic within the next nine months. As part of this initiative, there will be a change to the firm’s corporate name and trading symbol, which is expected to occur in January.
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Followers
|
136
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6316
|
Created
|
11/12/14
|
Type
|
Free
|
Moderators |
Our lead candidate, THCVHS, a proprietary prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT).
Previous US government studies in humans discovered that THC was able to reduce intraocular pressure (IOP), which is in part responsible for the crush-like injury to the cells of the optic nerve that can eventually result in blindness. Additional preclinical studies have shown the potential for THC to also provide neuroprotective benefit, which may be especially important to patients with glaucoma who are experiencing disease progression with normal IOP levels.
One of the major drawbacks of previous studies of the use of THC for glaucoma was that they relied on inhalation or ingestion of THC. These systemic routes of drug administration cause negative side effects like psychotropic effects and potentially decreasing blood pressure , which resulted in the American Academy of Opthamology determining that the adverse effects of systemic cannabis administration/consumption outweighed its therapeutic benefit.
At Skye Bioscience, we chemically modify THC to create a unique synthetic molecule with the intent to safely realize the known positive effects of THC. Our molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases.
Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. Damage to the optic nerve is caused by increased intraocular pressure (IOP) due to improper drainage and/or overproduction of fluid in the eye.
According to the American Academy of Ophthalmology, glaucoma affects over 75million people worldwide and is the leading cause of blindness in adults aged 60 and older.
Current therapies can lower IOP but progressive tolerance requires switching or combining drugs. They do NOT provide neuroprotective capabilities.
In preclinical studies, Skye’s THCVHS demonstrated the potential to significantly reduce intraocular pressure (IOP) – exceeding the capabilities of leading commercialized drugs in the current glaucoma market.
Additionally, it has been demonstrated:
We develop novel and proprietary classes of synthetic molecules through the modification of naturally derived systems.
Shifting the solutions paradigm on a effective treatment of diseases through the development of novel neuroprotective solutions.
Science First
The foundation of Skye Bioscience.
Revolutionary Solutions
Solving unmet needs of diseases with limited treatment offerings.
Product-led
Commercial differentiated applications to provide therapeutic benefits.
Impact driven
Change makers. Platform solutions that can extend beyond a single disease.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Diep brings more than 15 years of scientific and clinical research experience to Skye Bioscience. Prior to joining Skye, Mr. Diep was at Protox Therapeutics Inc.
Richard has more than 30 years of business experience and served as a Vice President to CFO on multiple companies in a wide range of industries both public and private, domestic and international.
Mr. Kim serves as the General Counsel and Director of IP at Emerald Bioscience. He is an experienced biotech executive and corporate attorney, and a registered patent attorney.
Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc. Prior to joining Skye, Mr. Takhar was at Emerald Health Sciences.
Mr. Dhillon was the co-founder, CEO, and director of OncoSec Medical Inc., a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors.
Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies.
Dr. Dalesandro is the President of Brecon Pharma Consulting, a full-service biotech consultancy firm focused on identifying and obtaining critical information early in product development.
Dr. Muñoz is a Professor of Immunology in the Department of Cell Biology, Physiology, and Immunology of the University of Córdoba, Spain.
Dr. Pasquale is a Professor of Organic Chemistry, Department of Pharmaceutical Sciences at the University of Eastern Piedmont, Novara, Italy, where his research activities focus on isolation ..
Dr. Goldberg is the Professor and Chair of Ophthalmology and Director of the Spencer Center for Vision Research at the Byers Eye Institute at Stanford University.
Dr. Pasquale is the Professor of Ophthalmology at the Icahn School of Medicine at Mount Sinai in New York City.
Dr. Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Clinical Professor of Ophthalmology at the Mt. Sinai Medical School and Surgeon Director Emeritus.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |